AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Part of paid clinical trials in Dothan, Alabama.

Sponsor
AstraZeneca
Study ID
NCT07611110
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD2265 — DRUG
    IV
  • Cabazitaxel — DRUG
    IV in combination with oral prednisone/prednisolone
  • Abiraterone — DRUG
    Oral in combination with prednisone/prednisolone
  • Enzalutamide — DRUG
    Oral
  • Apalutamide — DRUG
    Oral
  • Darolutamide — DRUG
    Oral
  • Rezvilutamide — DRUG
    Oral
  • Radium-223 — DRUG
    IV

Study Details

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Key Dates

Start date
May 4, 2026
Status verified
May 2026
Primary completion
Feb 13, 2029
Completion
Dec 20, 2029

Study Design

Enrollment
670 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    AZD2265
  • Active Comparator: Arm B
    Investigator's choice of cabazitaxel, ARPI switch, or radium-223

Primary Outcome Measure

Radiographic Progression-Free Survival (rPFS) [ Time Frame: From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months) ]

Central Contacts

Locations (24)

FacilityCityStateZIPSite coordinators
Research SiteDothanAlabama36303-
Research SitePhoenixArizona85004-
Research SiteIrvineCalifornia92618-
Research SiteLoma LindaCalifornia92354-
Research SiteSan FranciscoCalifornia94143-
Research SiteAuroraColorado80045-
Research SiteMiamiFlorida33165-
Research SiteO'FallonIllinois62269-
Research SiteMetairieLouisiana70006-
Research SiteDetroitMichigan48201-
Research SiteGrand RapidsMichigan49503-
Research SiteOmahaNebraska68130-
Research SiteOmahaNebraska68130-
Research SiteAlbuquerqueNew Mexico87109-
Research SiteNew Hyde ParkNew York11042-
Research SiteNew YorkNew York10065-
Research SiteClevelandOhio44195-
Research SiteDaytonOhio45415-
Research SitePortlandOregon97239-
Research SitePittsburghPennsylvania15232-
Research SiteMyrtle BeachSouth Carolina29572-
Research SiteNashvilleTennessee37203-
Research SiteHoustonTexas77042-
Research SiteSalt Lake CityUtah84106-

Find similar trials in Dothan, AL

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Research Site· Dothan, ALResearch Site· Phoenix, AZResearch Site· Irvine, CAResearch Site· Loma Linda, CAResearch Site· San Francisco, CAResearch Site· Aurora, CO

Related Studies